drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Anti-HER2 IgG1 monoclonal antibody that binds the HER2 extracellular domain IV, inhibiting receptor phosphorylation and downstream PI3K/AKT and MAPK signaling (extracellular blockade).
nci_thesaurus_concept_id
C179282
nci_thesaurus_definition
An Fc-engineered monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential immunomodulating and antineoplastic activities. Upon administration, inetetamab targets and specifically binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit proliferation of HER2-expressing tumor cells. In addition, the Fab region of inetetamab may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.
drug_mesh_term
Antibodies, Monoclonal, Humanized
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fc-engineered humanized IgG1 monoclonal antibody that binds the HER2 extracellular domain IV, blocking HER2-mediated receptor phosphorylation and downstream PI3K/AKT and MAPK signaling, and engaging immune effector functions to induce ADCC against HER2-overexpressing tumor cells.
drug_name
Inetetamab
nct_id_drug_ref
NCT06641544